Effects ofCOVID-19 on Parkinson's Disease Clinical Features: ACommunity-Based Case-ControlStudy

被引：141

作者：

Cilia, Roberto ^{[1
]}

Bonvegna, Salvatore ^{[1
]}

Straccia, Giulia ^{[1
,2
]}

Andreasi, Nico Golfre ^{[1
]}

Elia, Antonio E. ^{[1
]}

Romito, Luigi M. ^{[1
]}

Devigili, Grazia ^{[1
]}

Cereda, Emanuele ^{[3
]}

Eleopra, Roberto ^{[1
]}

机构：

[1] Fdn IRCCS Ist Neurol Carlo Besta, Dept Clin Neurosci, Parkinson & Movement Disorders Unit, Milan, Italy

[2] Univ Campania, Dept Med Sci & Adv Surg, Naples, Italy

[3] Fdn IRCCS Policlin San Matteo, Clin Nutr & Dietet Unit, Pavia, Italy

来源：

MOVEMENT DISORDERS | 2020年 / 35卷 / 08期

关键词：

BASAL GANGLIA;

D O I：

10.1002/mds.28170

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The impact of coronavirus disease 2019 (COVID-19) on clinical features of Parkinson's disease (PD) has been poorly characterized so far. Of 141 PD patients resident in Lombardy, we found 12 COVID-19 cases (8.5%), whose mean age and disease duration (65.5 and 6.3 years, respectively) were similar to controls. Changes in clinical features in the period January 2020 to April 2020 were compared with those of 36 PD controls matched for sex, age, and disease duration using the clinical impression of severity index for PD, the Movement Disorders Society Unified PD Rating Scale Parts II and IV, and the nonmotor symptoms scale. Motor and nonmotor symptoms significantly worsened in the COVID-19 group, requiring therapy adjustment in one third of cases. Clinical deterioration was explained by both infection-related mechanisms and impaired pharmacokinetics of dopaminergic therapy. Urinary issues and fatigue were the most prominent nonmotor issues. Cognitive functions were marginally involved, whereas none experienced autonomic failure. (c) 2020 International Parkinson and Movement Disorder Society

引用

页码：1287 / 1292

页数：6

共 30 条

[1]

ANTONINI A, 2020, MOVEMENT DISORD 0528

[2]

ASADIPOOYA AA, 2020, NEUROL SCI 0304

[3] Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study [J].

Bi, Qifang ;

Wu, Yongsheng ;

Mei, Shujiang ;

Ye, Chenfei ;

Zou, Xuan ;

Zhang, Zhen ;

Liu, Xiaojian ;

Wei, Lan ;

Truelove, Shaun A. ;

Zhang, Tong ;

Gao, Wei ;

Cheng, Cong ;

Tang, Xiujuan ;

Wu, Xiaoliang ;

Wu, Yu ;

Sun, Binbin ;

Huang, Suli ;

Sun, Yu ;

Zhang, Juncen ;

Ma, Ting ;

Lessler, Justin ;

Feng, Tiejian .

LANCET INFECTIOUS DISEASES, 2020, 20 (08) :911-919

[4]

Bloem B R., 2020, JAMA Neurology

[5]

Brooks Samantha K, 2020, Lancet, V395, P912, DOI [10.1016/S0140-6736(20)30460-8., 10.1016/S0140-6736(20)30460-8]

[6] Why is there motor deterioration in Parkinson’s disease during systemic infections-a hypothetical view [J].

Florian Brugger ;

Roberto Erro ;

Bettina Balint ;

Georg Kägi ;

Paolo Barone ;

Kailash P Bhatia .

npj Parkinson's Disease, 1 (1)

[7] Validation of the Italian version of the Non Motor Symptoms Scale for Parkinson's disease [J].

Cova, I. ;

Di Battista, M. E. ;

Vanacore, N. ;

Papi, C. P. ;

Alampi, G. ;

Rubino, A. ;

Valente, M. ;

Meco, G. ;

Contri, P. ;

Di Pucchio, A. ;

Lacorte, E. ;

Priori, A. ;

Mariani, C. ;

Pomati, S. .

PARKINSONISM & RELATED DISORDERS, 2017, 34 :38-42

[8]

Dipartimento della Protezione Civile, COVID 19 IT MON SIT

[9] Cytokine effects on the basal ganglia and dopamine function: The subcortical source of inflammatory malaise [J].

Felger, Jennifer C. ;

Miller, Andrew H. .

FRONTIERS IN NEUROENDOCRINOLOGY, 2012, 33 (03) :315-327

[10]

Giuseppe De Filippis M. B., 2020, RAPPORTI ISS COVID 1

← 1 2 3 →